Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine
- PMID: 28657444
- PMCID: PMC8286171
- DOI: 10.1080/14779072.2017.1348228
Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine
Abstract
Lipid-lowering therapy effectively decreases cardiovascular risk on a population level, but it remains difficult to identify an individual patient's personal risk reduction while following guideline directed medical therapy, leading to overtreatment in some patients and cardiovascular events in others. Recent improvements in cardiac CT technology provide the ability to directly assess an individual's atherosclerotic disease burden, which has the potential to personalize risk assessment for lipid-lowering therapy. Areas covered: We review the current unmet need in identifying patients at elevated residual risk despite guideline directed medical therapy, the evidence behind plaque regression as a potential marker of therapeutic response, and highlight state-of-the-art advances in coronary computed tomographic angiography (CCTA) for measurement of quantitative and qualitative changes in coronary atherosclerosis over time. Literature search was performed using PubMed and Google Scholar for literature relevant to statin therapy and residual risk, coronary plaque regression measurement, and CCTA assessment of quantitative and qualitative change in coronary atherosclerosis. Expert commentary: We discuss the potential ability of CCTA to guide lipid-lowering therapy as a bridge between population and personalized medicine in the future, as well as the potential barriers to its use.
Keywords: Cardiac computed tomography; PCSK-9; coronary atherosclerosis; coronary computed tomographic angiography; lipid-lowering therapy; personalized medicine; plaque regression; statin.
Conflict of interest statement
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Figures





Similar articles
-
Emerging Role of Coronary Computed Tomography Angiography in Lipid-Lowering Therapy: a Bridge to Image-Guided Personalized Medicine.Curr Cardiol Rep. 2019 Jun 21;21(8):72. doi: 10.1007/s11886-019-1170-4. Curr Cardiol Rep. 2019. PMID: 31228004 Review.
-
Bridging Prevention and Imaging: The Influence of Statins on CAC and CCTA Findings.Curr Atheroscler Rep. 2025 Apr 8;27(1):50. doi: 10.1007/s11883-025-01287-x. Curr Atheroscler Rep. 2025. PMID: 40198377 Review.
-
Use of coronary artery calcium score and coronary CT angiography to guide cardiovascular prevention and treatment.Ther Adv Cardiovasc Dis. 2024 Jan-Dec;18:17539447241249650. doi: 10.1177/17539447241249650. Ther Adv Cardiovasc Dis. 2024. PMID: 38708947 Free PMC article. Review.
-
Role of the screening with coronary computed tomography angiography on lipid management and risk factors control in an asymptomatic Chinese population: a community-based, parallel-group, open-label, randomized clinical trial (RESPECT2).Trials. 2024 Sep 30;25(1):635. doi: 10.1186/s13063-024-08469-z. Trials. 2024. PMID: 39350195 Free PMC article.
-
Cardiovascular risk stratification by coronary computed tomography angiography imaging: current state-of-the-art.Eur J Prev Cardiol. 2022 Mar 30;29(4):608-624. doi: 10.1093/eurjpc/zwab067. Eur J Prev Cardiol. 2022. PMID: 33930129 Review.
Cited by
-
Comprehensive analysis of the diagnostic and therapeutic value of the hypoxia-related gene PLAUR in the progression of atherosclerosis.Sci Rep. 2023 May 26;13(1):8533. doi: 10.1038/s41598-023-35548-z. Sci Rep. 2023. PMID: 37237021 Free PMC article.
-
Old and New NICE Guidelines for the Evaluation of New Onset Stable Chest Pain: A Real World Perspective.Biomed Res Int. 2018 Nov 8;2018:3762305. doi: 10.1155/2018/3762305. eCollection 2018. Biomed Res Int. 2018. PMID: 30533431 Free PMC article. Review.
-
Electron paramagnetic resonance oximetry as a novel approach to monitor the effectiveness and quality of red blood cell transfusions.Blood Transfus. 2019 Jul;17(4):296-306. doi: 10.2450/2019.0037-19. Epub 2019 May 16. Blood Transfus. 2019. PMID: 31184583 Free PMC article.
-
miR-33 Silencing Reprograms the Immune Cell Landscape in Atherosclerotic Plaques.Circ Res. 2021 Apr 16;128(8):1122-1138. doi: 10.1161/CIRCRESAHA.120.317914. Epub 2021 Feb 17. Circ Res. 2021. PMID: 33593073 Free PMC article.
-
Prognostic Value and Therapeutic Perspectives of Coronary CT Angiography: A Literature Review.Biomed Res Int. 2018 Sep 16;2018:6528238. doi: 10.1155/2018/6528238. eCollection 2018. Biomed Res Int. 2018. PMID: 30306089 Free PMC article. Review.
References
-
- Murray CJ et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The lancet 380, 2197–2223 (2013). - PubMed
-
- Mozaffarian D. et al. Heart Disease and Stroke Statistics—2016 Update A Report From the American Heart Association. Circulation, CIR. 0000000000000350 (2015). - PubMed
-
-
Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. Journal of the American College of Cardiology 46, 1225–1228 (2005).
*Early paper describing residual risk within cardiovascular therapy
-
-
- Holmes C, Schulzer M. & Mancini G. Angiographic results of lipid-lowering trials: a systematic review and meta-analysis. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc, 191–220 (2000).
-
- Tsujita K. et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. Journal of the American College of Cardiology 66, 495–507 (2015). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous